HUTCHMED to Divest 45% Equity Stake in Shanghai Hutchison Pharmaceuticals for $608 Million

MT Newswires Live01-02

HUTCHMED (HCM) said Wednesday it has agreed to sell a 45% equity interest in Shanghai Hutchison Pharmaceuticals to GP Health Service Capital and Shanghai Pharmaceuticals in two transactions totaling about $608 million in cash.

Shanghai Hutchison, which manufactures, sells and distributes prescription medicines for cardiovascular diseases, is HUTCHMED's 50-50 joint venture with Shanghai Pharmaceuticals.

Under the terms, GP Health Service has agreed to acquire a 35% equity interest in Shanghai Hutchison for about $473 million in cash, while Shanghai Pharmaceuticals will buy a 10% stake for about $135 million in cash.

The transactions are set to close by the end of Q1.

Upon completion, HUTCHMED will retain a 5% equity interest in Shanghai Hutchison. Meanwhile, Shanghai Pharmaceuticals will hold a 60% equity interest in the joint venture.

The sale will allow HUTCHMED to focus on its core business of developing and commercializing therapies for cancers and immunological diseases, the company said, adding that it plans to use proceeds of about $477 million to further enhance its pipeline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2500912866?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-02 16:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2500912866","market":"fut","top_or_hot":-1,"title":"HUTCHMED to Divest 45% Equity Stake in Shanghai Hutchison Pharmaceuticals for $608 Million","media":"MT Newswires Live","content":"<html><body><p> HUTCHMED (HCM) said Wednesday it has agreed to sell a 45% equity interest in Shanghai Hutchison Pharmaceuticals to GP Health Service Capital and Shanghai Pharmaceuticals in two transactions totaling about $608 million in cash.</p><p>Shanghai Hutchison, which manufactures, sells and distributes prescription medicines for cardiovascular diseases, is HUTCHMED's 50-50 joint venture with Shanghai Pharmaceuticals.</p><p>Under the terms, GP Health Service has agreed to acquire a 35% equity interest in Shanghai Hutchison for about $473 million in cash, while Shanghai Pharmaceuticals will buy a 10% stake for about $135 million in cash.</p><p>The transactions are set to close by the end of Q1.</p><p>Upon completion, HUTCHMED will retain a 5% equity interest in Shanghai Hutchison. Meanwhile, Shanghai Pharmaceuticals will hold a 60% equity interest in the joint venture.</p><p>The sale will allow HUTCHMED to focus on its core business of developing and commercializing therapies for cancers and immunological diseases, the company said, adding that it plans to use proceeds of about $477 million to further enhance its pipeline.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HUTCHMED to Divest 45% Equity Stake in Shanghai Hutchison Pharmaceuticals for $608 Million</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHUTCHMED to Divest 45% Equity Stake in Shanghai Hutchison Pharmaceuticals for $608 Million\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-02 16:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>HUTCHMED (HCM) said Wednesday it has agreed to sell a 45% equity interest in Shanghai Hutchison Pharmaceuticals to GP Health Service Capital and Shanghai Pharmaceuticals in two transactions totaling ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2500912866","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2500912866","pubTimestamp":1735807688,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"HUTCHMED (HCM) said Wednesday it has agreed to sell a 45% equity interest in Shanghai Hutchison Pharmaceuticals to GP Health Service Capital and Shanghai Pharmaceuticals in two transactions totaling a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","EQR":"资产住宅公司","00013":"和黄医药","BK4585":"ETF&股票定投概念","HCM":"和黄医药","BK4588":"碎股","BK4007":"制药","BK1587":"次新股","BK1588":"回港中概股","BK4215":"住宅房地产投资信托","BK4531":"中概回港概念"},"translate_title":"和黄医药将以6.08亿美元剥离上海和黄药业45%股权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00013":1,"EQR":1,"HCM":0.9},"content_text":"HUTCHMED (HCM) said Wednesday it has agreed to sell a 45% equity interest in Shanghai Hutchison Pharmaceuticals to GP Health Service Capital and Shanghai Pharmaceuticals in two transactions totaling about $608 million in cash.Shanghai Hutchison, which manufactures, sells and distributes prescription medicines for cardiovascular diseases, is HUTCHMED's 50-50 joint venture with Shanghai Pharmaceuticals.Under the terms, GP Health Service has agreed to acquire a 35% equity interest in Shanghai Hutchison for about $473 million in cash, while Shanghai Pharmaceuticals will buy a 10% stake for about $135 million in cash.The transactions are set to close by the end of Q1.Upon completion, HUTCHMED will retain a 5% equity interest in Shanghai Hutchison. Meanwhile, Shanghai Pharmaceuticals will hold a 60% equity interest in the joint venture.The sale will allow HUTCHMED to focus on its core business of developing and commercializing therapies for cancers and immunological diseases, the company said, adding that it plans to use proceeds of about $477 million to further enhance its pipeline.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2500912866"}